Space does not permit their full descriptions, but a rapid expansion of the number of non-surgical models to study atherosclerosis regression is expected based on the combined use of PCSK9-adenovectors to make mice LDLR-deficient, followed by antisense oligonucleotides (ASOs) against APOB or MTTP to lower APOB-lipoproteins (127, 128). Here, LDLR is linked to atherosclerosis.